Mettler-Toledo International, Inc. Free cash flow decreased by 33.5% to $122.38M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 30.9%, from $177.19M to $122.38M. Over 4 years (FY 2021 to FY 2025), Free cash flow shows relatively stable performance with a 1.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $222.78M | $240.87M | $203.32M | $71.69M | $175.92M | $218.61M | $271.62M | $130.07M | $238.06M | $243.34M | $249.09M | $172.60M | $233.70M | $233.25M | $224.91M | $177.19M | $212.49M | $274.88M | $184.08M | $122.38M |
| QoQ Change | — | +8.1% | -15.6% | -64.7% | +145.4% | +24.3% | +24.2% | -52.1% | +83.0% | +2.2% | +2.4% | -30.7% | +35.4% | -0.2% | -3.6% | -21.2% | +19.9% | +29.4% | -33.0% | -33.5% |
| YoY Change | — | — | — | — | -21.0% | -9.2% | +33.6% | +81.4% | +35.3% | +11.3% | -8.3% | +32.7% | -1.8% | -4.1% | -9.7% | +2.7% | -9.1% | +17.9% | -18.2% | -30.9% |